AKESO(HK:09926) 智通财经网·2025-06-12 23:50Group 1 - The company,药捷安康-B (02617), plans to conduct a global offering of 15.281 million H shares from June 13 to June 18, 2025, with a share price of HKD 13.15 and a 15% over-allotment option [1] - The company focuses on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, with a mission to provide innovative and differentiated treatment solutions globally [1] - The company has established a pipeline of six clinical-stage candidates and one preclinical candidate, aiming to expand its pipeline further through in-depth research in translational medicine and drug design [1] Group 2 - The company has entered into cornerstone investment agreements with five cornerstone investors, who have agreed to subscribe for shares totaling approximately HKD 130 million [2] - Based on the share price of HKD 13.15, cornerstone investors will acquire approximately 978.95 million shares [2] - The company estimates a net proceeds of approximately HKD 161 million from the global offering, with 90% allocated to fund a multi-regional Phase III clinical trial for its core product, Tinengotinib, and 10% for general operational expenses [2]